Currently, there are 49.82M common shares owned by the public and among those 24.58M shares have been available to trade.
The company’s stock has a 5-day price change of 67.34% and 19.20% over the past three months. MLYS shares are trading 21.53% year to date (YTD), with the 12-month market performance up to 6.86% higher. It has a 12-month low price of $8.24 and touched a high of $15.25 over the same period. MLYS has an average intraday trading volume of 281.20K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 49.65%, 42.85%, and 24.21% respectively.
Institutional ownership of Mineralys Therapeutics Inc (NASDAQ: MLYS) shares accounts for 54.66% of the company’s 49.82M shares outstanding.
It has a market capitalization of $745.54M and a beta (3y monthly) value of 1.13. The earnings-per-share (ttm) stands at -$3.64. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.39% over the week and 10.05% over the month.
Earnings per share for the fiscal year are expected to decrease by -3.11%, and -0.37% over the next financial year. EPS should grow at an annualized rate of -3.25% over the next five years, compared to -170.42% over the past 5-year period.
Looking at the support for the MLYS, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on July 10, 2024, with the firm’s price target at $30. Goldman coverage for the Mineralys Therapeutics Inc (MLYS) stock in a research note released on April 02, 2024 offered a Buy rating with a price target of $30. Wells Fargo was of a view on March 07, 2023 that the stock is Overweight, while Stifel gave the stock Buy rating on March 07, 2023, issuing a price target of $45. Guggenheim on their part issued Buy rating on March 07, 2023.
